← Back to Clinical Trials
Recruiting NCT07536542

NCT07536542 Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07536542
Status Recruiting
Phase
Sponsor Ankara University
Condition Parkinson Disease (PD)
Study Type INTERVENTIONAL
Enrollment 38 participants
Start Date 2026-04-24
Primary Completion 2026-07-24

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Dual-Task Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 38 participants in total. It began in 2026-04-24 with a primary completion date of 2026-07-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to investigate the effects of dual-task training on upper extremity function and muscle thickness in individuals with Parkinson's disease. The main questions it aims to answer are: Does dual-task training improve upper extremity function in individuals with Parkinson's disease? Does dual-task training lead to changes in upper extremity muscle thickness measured by ultrasonography? Researchers will compare a dual-task training group with a control group receiving routine care to determine whether 8 weeks of dual-task training results in greater improvements in upper extremity outco Participants will: complete baseline and post-intervention assessments of upper extremity function, muscle thickness, grip strength, and pinch strength be assigned to either a control group or a dual-task training group receive dual-task training 3 days per week for 8 weeks if assigned to the intervention group

Eligibility Criteria

Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist * Modified Hoehn and Yahr stage 2 to 3 * No medication or dosage change within the last 6 months * Cognitive capacity sufficient to understand and follow instructions, defined as Montreal Cognitive Assessment score ≥21 * Voluntary participation with written informed consent Exclusion Criteria: * Atypical or secondary parkinsonism * Advanced orthopedic condition affecting the upper extremity * Surgery, trauma, or immobilization involving the upper extremity within the last 6 months * Wound or dermatological condition preventing upper extremity ultrasonographic evaluation * Severe visual or hearing loss * Severe depression, psychosis, or communication difficulty * Any additional health problem preventing regular participation in the study

Contact & Investigator

Central Contact

Büşra Seçkinoğulları Korkusuz, PhD

✉ bskorkusuz@ankara.edu.tr

📞 +905442436914

Principal Investigator

Büşra Seçkinoğulları Korkusuz

PRINCIPAL INVESTIGATOR

Ankara University

Frequently Asked Questions

Who can join the NCT07536542 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 65 Years, studying Parkinson Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07536542 currently recruiting?

Yes, NCT07536542 is actively recruiting participants. Contact the research team at bskorkusuz@ankara.edu.tr for enrollment information.

Where is the NCT07536542 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07536542 clinical trial?

NCT07536542 is sponsored by Ankara University. The principal investigator is Büşra Seçkinoğulları Korkusuz at Ankara University. The trial plans to enroll 38 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology